newsfilter
← Latest News
PR Newswire·

Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Second Quarter 2022 Financial Results

THE-630 Phase 1/2 clinical trial enrolling patients; initial data expected in Q2 2023 Nomination of development candidate for fourth-generation epidermal growth factor receptor (EGFR) inhibitor program expected in Q3 2022; IND expected in 2023 $228.6